Kringle PharmaTSE:4884 -0.88%45 Current Ratio is 4.79 as of Mar. 2026, which is 75% below its 10-year median of 19.19. GuruFocus rates TSE:4884 with a GF Score™ of 45/100 and a GF Value™ of 円495.40 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,411 Biotechnology companies, Kringle Pharma ranks better than 56.56% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Kringle Pharma's current ratio for the quarter that ended in Mar. 2026 was 4.79.
Kringle Pharma has a current ratio of 4.79. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Kringle Pharma's Current Ratio or its related term are showing as below:
TSE:4884'
s Current Ratio Range Over the Past 10 Years
Min: 4.79 Med: 19.19 Max: 66.35
Current: 4.79
During the past 8 years, Kringle Pharma's highest Current Ratio was 66.35. The lowest was 4.79. And the median was 19.19.
TSE:4884's Current Ratio is ranked better than 56.56% of 1411
companies
in the Biotechnology industry
Industry Median: 3.91
vs TSE:4884: 4.79
Kringle Pharma (TSE:4884) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Kringle Pharma Current Ratio Related Terms
Kringle Pharma Current Ratio Historical Data
* Premium members only.
The historical data trend for Kringle Pharma's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4884 vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, Kringle Pharma's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kringle Pharma Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kringle Pharma's Current Ratio distribution charts can be found below:
* The bar in red indicates where Kringle Pharma's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kringle Pharma (TSE:4884) has a Current Ratio of 4.79 as of Mar. 2026. This is 75% below median its historical median of 19.19. Over the past decade, Kringle Pharma's Current Ratio has ranged from 4.79 to 66.35. According to the industry distribution chart, Kringle Pharma ranks #613 out of 1411 companies in the Biotechnology industry, placing it in the top 43.4%.
Is Kringle Pharma's Current Ratio too high?
Kringle Pharma's current Current Ratio of 4.79 is 75% below median its 10-year median of 19.19. Over the past 10 years, this metric has ranged from a low of 4.79 to a high of 66.35. The Biotechnology industry median Current Ratio is 3.91. Kringle Pharma's value of 4.79 is 22.5% above this industry median. Based on the distribution chart, Kringle Pharma ranks #613 out of 1411 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Kringle Pharma has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Kringle Pharma's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Kringle Pharma ranks #613 out of 1411 companies for Current Ratio. This puts Kringle Pharma in the upper half of its industry. The industry median Current Ratio is 3.91. Kringle Pharma's value of 4.79 is 22.5% above this benchmark. Historically, Kringle Pharma's own Current Ratio has ranged from 4.79 to 66.35 over the past decade. While the company's 10-year median is 19.19 vs. the industry median of 3.91, Kringle Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.91, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kringle Pharma's current Current Ratio of 4.79 is 22.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kringle Pharma's current Current Ratio is 4.79, which is 75% below median its own 10-year median of 19.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kringle Pharma stock overvalued right now?
Based on GuruFocus' analysis, Kringle Pharma (TSE:4884) is currently considered Possible Value Trap. The stock's GF Value™ is 円495.40, compared to a current price of 円339.00 — trading 31.6% below its estimated fair value. The current Current Ratio is 4.79, which is 75% below median its 10-year median of 19.19 and 22.5% above the Biotechnology industry median of 3.91. Kringle Pharma's overall GF Score™ is 45/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Kringle Pharma (TSE:4884), the current Current Ratio is 4.79 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kringle Pharma (TSE:4884) Overvalued in 2026?
Based on GuruFocus' analysis, Kringle Pharma stock appears to be undervalued.
The current stock price of 円339.00 is trading 31.6% below its estimated GF Value™ of 円495.40.
GuruFocus considers Kringle Pharma to be Possible Value Trap.
Key valuation signals for TSE:4884:
Current Ratio: 4.79 (75% below median its 10-year median of 19.19)
GF Value™: 円495.40 vs. price of 円339.00 (31.6% below fair value)
Industry Position: 22.5% above the Biotechnology median (#613 of 1411)
No single metric tells the full story. See the TSE:4884 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kringle Pharma Inc is engaged in the research and development of HGF (hepatocyte growth factor) protein as a therapeutic agent for intractable diseases. The Company operates in a single segment, pharmaceutical development.
45GF Score
Get the complete analysis for TSE:4884
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4884 has been successfully added to your 
